Skye Bioscience, Inc. (SKYE) Dividend History

Company News

• Skye Bioscience to Participate in Upcoming Investment Conferences

  Skye Bioscience, a clinical-stage biotechnology company, announced its participation in upcoming healthcare conferences and a partnership with Arecor Therapeutics to develop an enhanced formulation of its obesity candidate, nimacimab.

  GlobeNewswire Inc.
• Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

  Skye Bioscience and Arecor Therapeutics have partnered to develop an enhanced formulation of Skye's obesity candidate nimacimab using Arecor's proprietary technology. The collaboration aims to improve patient compliance and treatment outcomes for this first-in-class CB1-inhibiting monoclonal antibody.

  GlobeNewswire Inc.
• Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025

  Skye Bioscience, a clinical-stage biotechnology company, will host a conference call to discuss its 2024 fourth quarter and full-year financial results. The company is focused on developing next-generation molecules to treat obesity and other metabolic health disorders.

  GlobeNewswire Inc.
• Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  Skye Bioscience, a clinical-stage biopharmaceutical company, announced that it has granted stock options to two new non-executive employees under its Amended and Restated 2024 Inducement Equity Incentive Plan. The stock options have an exercise price of $2.89 per share and will vest over four years.

  GlobeNewswire Inc.
• Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

  Skye Bioscience has achieved over 50% enrollment in its Phase 2 clinical trial for its CB1 inhibitor nimacimab in overweight or obese patients. The company expects to report interim data in Q2 2025 and believes nimacimab has a favorable safety profile compared to other CB1 inhibitors.

  GlobeNewswire Inc.